The need for guardrails with large language models in pharmacovigilance and other medical safety critical settings.

Journal: Scientific reports
Published Date:

Abstract

Large language models (LLMs) are useful tools with the capacity for performing specific types of knowledge work at an effective scale. However, LLM deployments in high-risk and safety-critical domains pose unique challenges, notably the issue of "hallucinations", where LLMs can generate fabricated information. This is particularly concerning in settings such as drug safety, where inaccuracies could lead to patient harm. To mitigate these risks, we have developed and demonstrated a proof of concept suite of guardrails specifically designed to mitigate certain types of hallucinations and errors for drug safety, with potential applicability to other medical safety-critical contexts. These guardrails include mechanisms to detect anomalous documents to prevent the ingestion of inappropriate data, identify incorrect drug names or adverse event terms, and convey uncertainty in generated content. We integrated these guardrails with an LLM fine-tuned for a text-to-text task, which involves converting both structured and unstructured data within adverse event reports into natural language. This method was applied to translate individual case safety reports, demonstrating effective application in a pharmacovigilance processing task. Our guardrail framework offers a set of tools with broad applicability across various domains, ensuring LLMs can be safely used in high-risk situations by eliminating the occurrence of key errors, including the generation of incorrect pharmacovigilance-related terms, thus adhering to stringent regulatory and quality standards in medical safety-critical environments.

Authors

  • Joe B Hakim
    Department of Health Sciences and Technology, Harvard-MIT, Cambridge, MA, USA.
  • Jeffery L Painter
    GlaxoSmithKline, Durham, NC, USA.
  • Darmendra Ramcharran
    GSK, Providence, RI, USA.
  • Vijay Kara
    GSK, London, UK.
  • Greg Powell
    Safety Innovation and Analytics, GSK, Durham, NC, USA.
  • Paulina Sobczak
    GSK, Warsaw, Poland.
  • Chiho Sato
    GSK, Tokyo, Japan.
  • Andrew Bate
    Pfizer, London, UK.
  • Andrew Beam
    Department of Biomedical Informatics, Harvard Medical School, Boston, MA, United States of America; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.